Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on November 12, 2015. The report details the closing of a registered direct offering of common stock and warrants.
Key Financial Metrics
- Gross Proceeds: Approximately $7.0 million.
- Shares Issued: 16,666,667 shares of common stock.
- Warrants Issued: Warrants to purchase 12,500,000 shares of common stock.
- Warrant Exercise Price: $0.53 per share.
- Unit Structure: One share of common stock plus a warrant to purchase 0.75 of a share.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational metrics.
Material Changes
The primary material change is the increase in capitalization resulting from the closing of the Offering. This transaction was previously announced in a Form 8-K filed on November 6, 2015.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a discussion of risks and contingencies beyond the disclosure of the capital raise. The transaction was executed with the legal opinion of Hogan Lovells US LLP regarding the legality of the issuance.
Investor Verification Checklist
- Verify the exact number of shares and warrants issued (16,666,667 shares and 12,500,000 warrants).
- Confirm the gross proceeds of approximately $7.0 million.
- Review the warrant terms, specifically the $0.53 exercise price and 0.75 share ratio per unit.
- Check the legal opinion filed as Exhibit 5.1 for any conditions on the issuance.
- Note that the registrant is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.